Genomic Medicine Sweden (GMS) - Acceleration of Implementation of Personalised Medicine for Rare Diseases and Cancer
Introduction and Moderation: Jan-Ingvar Jönsson, Swedish Research Council, Sweden
The policy perspective: Jenni Nordborg, National Coordinator Office for Life Science, Sweden
The patient’s perspective: Fabian Bolin, CEO & Co-founder, WarOnCancer AB and Sebastian Hermelin, COO & Co-founder, WarOnCancer AB, Sweden
The company’s perspective: Joachim Reischl, AstraZeneca, Sweden
Genomics Medicine Sweden (GMS): Richard Rosenquist, Head of GMS, Sweden
Clinical implementation of GMS: Anna Wedell, Karolinska University Hospital, Sweden
Swedish Research Council
Jan-Ingvar Jönsson is currently Secretary General for Medicine and Health at the Swedish Research Council, where he has held several commissions since 2013. His main responsibilities are the development of high quality research programs and funding schemes in medicine, life science and clinical research as well as in public health and health care research. He is also involved in different aspects of assessment and impact of research within the health care sector.
Jan-Ingvar has a background in immunology and obtained his PhD after five years at the Max-Planck-Institute in Freiburg, Germany. After working as postdoctoral researcher in stem cell biology at the Hospital for Sick Children in Toronto, Canada, he returned to Sweden in the mid 90’s to establish a career as independent investigator in haematology cancer biology, and drug targeting.
He is national representative of several international organisations and is since 2016 vice-chair of Joint programming initiative of antimicrobial resistance (JPIAMR). In addition, he is involved in collaboration between several other research funding agencies and policy makers worldwide. For example, he is chair of the joint committee of the Nordic medical research councils, board member of JPND in neurodegenerative diseases, and member of the Governing Council of WHO international agency for research on cancer (IARC).
National coordinator Office for Life Science, Sweden
Jenni Nordborg, PhD, is National Coordinator and Director of Life Sciences at the Government Offices of Sweden, heading the Office for Life Sciences. The Office for Life Sciences coordinates policy between the Ministry of Social Affairs, the Ministry of Research and Higher Education, the Ministry of Enterprise and Innovation, and is responsible for forming a new Swedish Life Science Strategy. Dr. Nordborg is also Director and Head of the Health Division at Vinnova, the Swedish Governmental Innovation Agency. She is active in strategic innovation policy development and implementation within health and life science on national and international level. Her network includes international innovation policy, entrepreneurship and the health and life science ecosystem.
Dr. Nordborg has a research background from Chalmers University of Technology, and experience from senior management positions in both the private and public sector. She has an entrepreneurial background from commercialization of research, and international marketing and sales experience. Together with the founding team she built up the laser company Cobolt AB to an international position. She also has experience in board level positions both in private companies and governmental organizations.
Fabian Bolin is the CEO & co-founder of WarOnCancer, a digital health company on a mission to radically improve mental health for people affected by cancer. The company is currently developing the WarOnCancer App - a storytelling platform for patients, survivors and loved ones.
Fabian studied business at Stockholm School of Economics followed by work in investment banking. He has also worked in the film industry as an actor.
After being diagnosed with leukemia, Fabian began documenting his cancer battle on a blog, which quickly gained global attention. He won the award “Journalist of the Year 2015” and recently ranked No. 1 as most influential in the Swedish MedTech industry 2018.
Sebastian Hermelin is COO and Co-Founder of WarOnCancer, a digital health company on a mission to radically improve mental health for people affected by cancer. Sebastian is leading WarOnCancer’s co-creation projects together with the biopharmaceutical- and healthcare industry. Amongst them the project ”Blockchain to Empower Patients” which aims to better understand the potential in patient-reported data and how this data can be collected in a continuous and sustainable way.
The company is currently developing the WarOnCancer App - a storytelling platform for patients, survivors and loved ones.
Sebastian has experience of work related to consumer retail, media and the financial sector. He holds a M.Sc in industrial Engineering, specializing in Energy Systems from the Royal Institute of Technology (KTH), Sweden.
Joachim Reischl joined AstraZeneca in 2015 as VP, Head of Precision Medicine Policy, Portfolio and Externalisation. In this role, Joachim is the Precision Medicine and Genomics site head in Gothenburg and a member of the global AstraZeneca Precision Medicine and Genomics leadership team responsible for diagnostic alliances and business excellence. Joachim has over 15 years pharmaceutical R&D experience. Before joining AstraZeneca, Joachim headed the Global Biomarker Strategy and Development function at Bayer. Joachim is passionate to drive transformational change in pharma to maximize innovation and productivity for the benefits of patients. He has a strong interest in next generation technologies and their application to precision medicine.
Karolinska University Hospital, Sweden
Richard Rosenquist Brandell is Professor of Clinical Genetics at Karolinska Institutet and Senior Physician in Clinical Genetics at Karolinska University Hospital, Sweden. He received his medical degree and PhD degree at Umeå University, Sweden, and undertook a postdoctoral period at the Department of Pathology, Frankfurt am Main, Germany. He became Professor of Molecular Hematology in 2007 at Uppsala University. He has initiated and led the SciLifeLab Clinical Genomics Facility in Uppsala between 2013-2017 and is currently Platform Director for the national Diagnostics Development Platform within SciLifeLab. More recently, he is coordinating the Genomics Medicine Sweden initiative that aims to build a new type of infrastructure within Swedish healthcare that implements precision medicine at a national level.
Karolinska University Hospital, Sweden
Anna Wedell, MD, PhD, is a Clinical Geneticist and Professor of Medical Genetics at the Department of Molecular Medicine & Surgery, Karolinska Institutet, and Head of the Centre for Inherited Metabolic Diseases (CMMS), Karolinska University Hospital. During 2010 – 2013, she was Clinical Director at SciLifeLab in Stockholm, developing clinical whole genome sequencing for diagnosis of rare diseases which has subsequently been implemented at the Karolinska University Hospital. Anna Wedell is Chairman of the Medical Nobel Committee, member of the Royal Swedish Academy of Sciences, and member of the Royal Swedish Academy of Engineering Sciences.
On 20/21 November 2018, the DLR Project Management Agency took part in the ICPerMed Conference 2018 'Personalised Medicine in Action' as one of the organisers. In its function as editor of the website of the 'ICPerMed International Consortium', the DLR Project Management Agency agreed to upload the presentations held during this event to this website thus making them available for download in pdf format subject to the express consent of the speakers concerned. DLR, as the uploading entity, has not monitored the contents of these presentations in any way. In case of incorrect contents, copyright infringements or other violations of the law, please contact the ICPerMed Secretariat (e-mail: ICPerMed@dlr.de). Any offending material will be removed immediately.